Antinuclear Antibody (ANA) Testing

Autoimmune rheumatic diseases are conditions in which the immune system attacks the joints and certain systems. They are often difficult to diagnose as their symptoms can be vague, vary from patient to patient, and often overlap with other clinical conditions. The diagnosis of autoimmune disease is based on patient signs and symptoms, clinical information, and laboratory test results. Testing of the antinuclear antibody (ANA) is a good first approach for laboratory evaluation of patients suspected of having certain autoimmune rheumatic diseases.

ANAs are a class of antibodies that bind to cellular components in the nucleus including proteins, DNA, RNA, and nucleic acid-protein complexes. The origin of ANA testing was first described in 1948 when Hargraves and colleagues observed the LE cells, described as mature polymorphonuclear leukocytes containing phagocytosed nuclear material. LE cells were so named because there were found only in a patient with systemic lupus erythematosus (SLE). Since then, ANA identification remains the most sensitive serologic marker for evaluation of patients with suspected connective tissue autoimmune disorders including systemic lupus erythematosus (SLE), Sjogren’s syndrome, and polymyositis/dermatomyositis. Although 20-30% of the average population has detectable levels of ANAs, increased titers are characteristic of individuals with connective tissue disorders. The table below shows the rheumatic disease associated with a positive ANA test.

Table 1. Rheumatic disease associated with a positive ANA test
Disease Sensitivity Specificity
System Lupus erythematosus 93-95 57
Sjogren’s syndrome 48 52
Systemic Sclerosis 85 54
Juvenile idiopathic arthritis 57 39
Juvenile idiopathic arthritis with uveitis 80 53
Rheumatoid arthritis 41 56
Polymyositis/dermatomyositis 61 63
Drug-induced Lupus* NA NA
Mixed connective tissue disease* NA NA

*For both drug-induced lupus and mixed connective tissue disease, the diagnostic criteria require a positive ANA, and therefore specificity and sensitivity cannot be determined

Retrieved from


Thus, the sensitivity and specificity of methods used to detect ANAs are very important to diagnose patients with autoimmune rheumatic disease.

Solaris Diagnostics laboratory can now provide screening for ANA with a turnaround time of 24 hours from the time the sample is received in the laboratory.

Benefits of Working with Solaris Diagnostics

Now you can provide patients with the quickest and most accurate diagnosis possible from our high-complexity, CLIA accredited laboratory. Choose Solaris Diagnostics for:

  • Simple collection
  • Results by 5:00 pm on the day the lab receives the specimen
  • Direct access to experienced scientific staff
  • Among the most personal customer service experiences in the industry

Our experts assist clinicians and health care providers in rapidly identifying the pathogens and underlying causes of disease. We know that fast and accurate diagnoses lead to better patient outcomes.

For more information call 844-550-0308 to speak with one of our staff. You may also use the form on our Contact Us page.

Continue Reading